Literature DB >> 15218534

RNA modulation, repair and remodeling by splice switching oligonucleotides.

Ryszard Kole1, Tiffany Williams, Lisa Cohen.   

Abstract

Targeting splicing by antisense oligonucleotides allows RNA modifications that are not possible with RNA interference or other antisense techniques that destine the RNA for destruction. By changing the ratio of naturally occurring splice variants the expression of mRNA is modulated. By preventing the use of an aberrant splice site created by a mutation and enforcing re-selection of correct splice sites the RNA is repaired. Antisense induced skipping of the exon that carries a nonsense mutation remodels the mRNA and restores the reading frame of the defective protein. All of the above approaches have clinical applications. Modulation of splice variants is particularly important since close to 60% of all genes code for alternatively spliced pre-mRNA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218534     DOI: 035001373

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  13 in total

1.  Sodium Butyrate and Valproic Acid as Splicing Restoring Agents in Erythroid Cells of β-Thalassemic Patients.

Authors:  Mahmoud Shekari Khaniani; Mahdieh Tagizadeh; Abbasali Hosseinpour Feizi; Sima Mansoori Derakhshan
Journal:  Iran J Biotechnol       Date:  2016-03       Impact factor: 1.671

2.  Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.

Authors:  Jonathan W Kotula; Elizabeth D Pratico; Xin Ming; Osamu Nakagawa; Rudolph L Juliano; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

Review 3.  Emerging role of alternative splicing of CRF1 receptor in CRF signaling.

Authors:  Michał A Zmijewski; Andrzej T Slominski
Journal:  Acta Biochim Pol       Date:  2010-03-16       Impact factor: 2.149

Review 4.  Delivery of oligonucleotides with lipid nanoparticles.

Authors:  Yuhua Wang; Lei Miao; Andrew Satterlee; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2015-02-27       Impact factor: 15.470

5.  Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Authors:  Annemieke Aartsma-Rus; Laura van Vliet; Marscha Hirschi; Anneke A M Janson; Hans Heemskerk; Christa L de Winter; Sjef de Kimpe; Judith C T van Deutekom; Peter A C 't Hoen; Gert-Jan B van Ommen
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

6.  A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.

Authors:  Takenori Shimo; Kana Hosoki; Yusuke Nakatsuji; Toshifumi Yokota; Satoshi Obika
Journal:  J Hum Genet       Date:  2018-01-16       Impact factor: 3.172

Review 7.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12

8.  Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms.

Authors:  Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Mol Cancer       Date:  2008-05-28       Impact factor: 27.401

9.  Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice.

Authors:  Jason H Williams; Rebecca C Schray; Shashank R Sirsi; Gordon J Lutz
Journal:  BMC Biotechnol       Date:  2008-04-02       Impact factor: 2.563

10.  Determining the impact of alternative splicing events on transcriptome dynamics.

Authors:  Emmanuelle Wilhelm; François-Xavier Pellay; Arndt Benecke; Brendan Bell
Journal:  BMC Res Notes       Date:  2008-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.